Y mAbs Therapeutics Cash Flow Conversion Efficiency
Y mAbs Therapeutics cash flow conversion efficiency. Based on the latest financial reports, Y mAbs Therapeutics (YMAB) has a cash flow conversion efficiency ratio of 0.019x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.65 Million) by net assets ($87.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Y mAbs Therapeutics (2016–2024)
Cash flow conversion efficiency of Y mAbs Therapeutics from 2016 to 2024. This chart illustrates how Y mAbs Therapeutics's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Y mAbs Therapeutics stock price today for real-time trading data and today's change.
Y mAbs Therapeutics Cash Flow Conversion Ratio Explained
Y mAbs Therapeutics cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Y mAbs Therapeutics Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Y mAbs Therapeutics ranked by their cash flow conversion efficiency. Also see YMAB stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ATN International Inc
NASDAQ:ATNI
|
0.033x |
|
Hartadinata Abadi Tbk PT
JK:HRTA
|
-0.477x |
|
Zhejiang Shouxiangu Pharm Co
SHG:603896
|
0.009x |
|
Patrimoine et Commerce SA
PA:PAT
|
0.036x |
|
Golden Flower Tbk PT
JK:POLU
|
0.204x |
|
YIDU TECH INC. DL -00002
F:0EL
|
N/A |
|
Pro Real Estate Investment Trust
TO:PRV-UN
|
0.019x |
|
Morrow Bank ASA
OL:MOBA
|
-0.029x |
Annual Cash Flow Conversion Efficiency for Y mAbs Therapeutics (2016–2024)
The table below shows the annual cash flow conversion efficiency of Y mAbs Therapeutics from 2016 to 2024. Review Y mAbs Therapeutics free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $92.00 Million | $-15.71 Million | -0.171x | +36.66% |
| 2023-12-31 | $100.98 Million | $-27.23 Million | -0.270x | +61.21% |
| 2022-12-31 | $109.22 Million | $-75.92 Million | -0.695x | -22.07% |
| 2021-12-31 | $180.11 Million | $-102.56 Million | -0.569x | +33.94% |
| 2020-12-31 | $105.84 Million | $-91.23 Million | -0.862x | -133.28% |
| 2019-12-31 | $198.90 Million | $-73.50 Million | -0.370x | -25.95% |
| 2018-12-31 | $140.53 Million | $-41.23 Million | -0.293x | -51.87% |
| 2017-12-31 | $82.15 Million | $-15.87 Million | -0.193x | +79.13% |
| 2016-12-31 | $12.06 Million | $-11.17 Million | -0.926x | -- |
About Y mAbs Therapeutics
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of radioimmunotherapy and antibody based therapeutic products for the treatment of cancer. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-ri… Read more